Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Shanghai Pharmaceutical
Asia
China's NRDL, Biocon-Viatris and more—Fierce Pharma Asia
China's new NRDL excludes pricey I-O meds. Biocon and Viatris are reportedly considering a biosimilar merger. A Chinese biotech got $200 million.
Angus Liu
Dec 10, 2021 8:45am
Syntegon and Shanghai Pharma to build lab for novel drug process
Dec 9, 2021 10:40am
China's PD-1s, Fujifilm, Sinopharm and more—Fierce Pharma Asia
Jan 8, 2021 9:08am
Shanghai Pharma maps $1.18B construction project in hometown hub
Jan 5, 2021 7:43am
FiercePharmaAsia—Astellas, Brii's $260M, Sun and more
May 25, 2018 9:30am
FiercePharmaAsia—Takeda, Shanghai Pharma, WuXi NextCODE
Jan 26, 2018 9:37am
